Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
BioMarin Pharmaceutical (BMRN) Stock Price & Analysis
1,827 Followers
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$73.68 - $99.56
Previous Close$84.59
Volume1.06M
Average Volume (3M)2.48M
Market Cap
$16.06B
Enterprise Value$16.10B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)79.2
Beta0.58
Next Earnings
Aug 05, 2024EPS Estimate
$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding189,879,803
10 Day Avg. Volume5,981,849
30 Day Avg. Volume2,479,773
Standard Deviation0.09
R-Squared0.04
Alpha-0.00134
Financial Highlights & Ratios
Price to Book (P/B)3.46
Price to Sales (P/S)24.62
Price to Cash Flow (P/CF)84.70
P/FCF Ratio251.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit8.46
Enterprise Value/Ebitda45.46
Forecast
1Y Price Target
$105.08Price Target Upside24.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Product EfficacyRoctavian demonstrated durable bleed control and sustained FVIII expression at four years in its Ph3 GENEr8-1 trial.
Revenue GrowthBMRN's guidance for 2027 could potentially reach $3.5 billion in revenue, driven by strong uptake for Voxzogo in achondroplasia.
ValuationBMRN is trading at valuations that may be considered low for its growth profile, potentially offering an attractive investment.
Bears Say
Competitive LandscapePfizer's gene therapy product demonstrated superior treatment reduction compared to BioMarin's Roctavian.
Market CompetitionBridgebio's data show their oral product is at least as effective as Voxzogo, posing a substantial long-term threat to BioMarin's growth.
Product EfficacyInfigratinib showed over 50% lower efficacy in femur growth compared to a lower dose in ACH mice models.
---
Ownership Overview
1.30% Insiders
39.37% Mutual Funds
23.97% Other Institutional Investors
35.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $73.67 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Aug 05, 2024 which is in 9 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Apr 24, 2024. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.312 by $0.148.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.36.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 189,879,800 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.46 in its last earnings report, beating expectations of $0.312. Following the earnings report the stock price went down -9.901%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.08 (24.22% Upside)
$105.08 (24.22% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.07%
12-Months-Change
Fundamentals
Return on Equity
4.22%
Trailing 12-Months
Asset Growth
6.82%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q1 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$105.08
▲(24.22% Upside)
Technical Analysis
Sangamo Biosciences
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+3.40%
reiterated a buy rating 5 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +3.40% per trade.
---